Checked.be
Active
BE 0719.285.286Private limited company
Vert
Klaverstraat(Kor) 11 ·8500 Kortrijk, Belgium· 7 yrs active
Sector: Specialist medical practice
(86220)
Conclusion
Vert has been active since 2019 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1.13M and a net result of €610k. Equity is growing by ~8% per year across the filed fiscal years. Its solvency ranks better than 58% of 90 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Based on the State Gazette, CBE and 4 annual accounts.
Key figures
| Equity | €1.13M |
| Net result | €610k |
| Better than sector | 58% |
| Active | 7 yrs |
Financial profile
93
/ 100
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Health
90
Profitability
100
Solvency
99
Growth
78
Stability
100
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
More than 3 years active
Founded in 2019, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
90
/ 100
Excellent
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€100k
estimate, not credit advice
Score history
93
2022
86
2023
100
2024
90
2025
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 1.98 (≥ 1.5)
+10
Quick ratio
Quick ratio 1.98 (≥ 1.0)
+5
Leverage
Debt/equity 0.57 (< 1.0)
+10
Profitability
ROE 54% (≥ 10%)
+10
Interest coverage
Interest coverage 18.0× (≥ 3×)
+8
Profit trend
Net profit down YoY
-3
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview
Annual accounts filed on 16-07-2026 with the NBB · fiscal year 2025 · abbreviated schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing
Equity: growth of ~8%/year over 4 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2025 · NACE 86, Human health activities · compared within the same schema type (abbreviated schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 63.6% | 56.8% | |
| Net result | €610k | €93k | |
| Equity | €1.13M | €202k | |
| Gross operating margin | €900k | €237k | |
| Total assets | €1.78M | €596k |
€899k
-4.3%
22-25
€610k
-6.3%
22-25
€682k
-6.9%
22-25
€1.78M
-14.4%
22-25
€1.13M
-3.5%
22-25
€586k
-3.4%
22-25
€198k
-8.6%
22-25
€651k
-
22-25
€648k
-28.5%
22-25
€598k
-29.8%
22-25
1.98
+15.7%
22-25
1.98
+15.7%
22-25
63.6%
+12.7%
22-25
0.57
-25.9%
22-25
53.9%
-2.9%
22-25
34.3%
+9.4%
22-25
18.04
-99.6%
22-25
Figures by fiscal year and ratios
Change versus the prior fiscal year, coloured by direction (green = favourable).
| Fiscal year | 2025 Δ | 2024 Δ | 2023 Δ | 2022 Δ |
|---|---|---|---|---|
| Deposit | abbreviated schema | abbreviated schema | abbreviated schema | abbreviated schema |
| Revenue | - | - | - | - |
| EBITDA | -4.3% | +14.2% | +93.1% | - |
| Net profit | -6.3% | +24.6% | +65.6% | - |
| Cash flow | -6.9% | +28.0% | +76.2% | - |
| Staff costs | - | - | - | - |
| Income taxes | -8.6% | -9.1% | +135.1% | - |
| Dividends | - | -100.0% | +1.9% | - |
| Total assets | -14.4% | +42.9% | +16.6% | - |
| Equity | -3.5% | +124.6% | -45.4% | - |
| Debt | -28.5% | -2.9% | +219.8% | - |
| of which ≤ 1y | -29.8% | -5.5% | +251.6% | - |
| of which > 1y | - | - | - | - |
| Working capital | -3.4% | +316.3% | -85.1% | - |
| Employees (FTE) | - | - | - | - |
Ratios (computed)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Current ratio | 1.98 | 1.71 | 1.16 | 4.82 |
| Quick ratio | 1.98 | 1.71 | 1.16 | 4.82 |
| Working capital ratio | 32.9% | 29.2% | 10.0% | 78.6% |
| Solvency | 63.6% | 56.4% | 35.9% | 76.6% |
| Debt / equity | 0.57 | 0.77 | 1.79 | 0.30 |
| Long-term debt ratio | - | - | - | - |
| Interest coverage | 18.04 | 4329.69 | 59.87 | 2429.83 |
| Gross margin | - | - | - | - |
| Net margin | - | - | - | - |
| ROA | 34.3% | 31.3% | 35.9% | 25.3% |
| ROE | 53.9% | 55.5% | 100.0% | 33.0% |
| EBITDA margin | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days inventory (DSI) | - | - | - | - |
Balance-sheet composition 2025
Full annual accounts (23 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Balance sheet, Assets | |||||
| TOTAL ASSETS | 20/58 | €1.78M | €2.08M | €1.45M | €1.25M |
| Fixed assets | 21/28 | €596k | €621k | €407k | €11k |
| Tangible fixed assets | 22/27 | €596k | €621k | €407k | €11k |
| Current assets | 29/58 | €1.18M | €1.46M | €1.05M | €1.24M |
| Amounts receivable within one year | 40/41 | €318k | €401k | €299k | €401k |
| Investments | 50/53 | €700k | €750k | - | - |
| Cash & bank | 54/58 | €157k | €301k | €734k | €836k |
| Balance sheet, Equity & liabilities | |||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €1.78M | €2.08M | €1.45M | €1.25M |
| Equity | 10/15 | €1.13M | €1.17M | €522k | €956k |
| Contributions / capital | 10/11 | - | - | €0 | €19k |
| Reserves | 13 | €1.13M | €1.17M | €522k | €938k |
| Accumulated profits (losses) | 14 | €0 | €0 | €0 | €0 |
| Amounts payable | 17/49 | €648k | €906k | €932k | €292k |
| Amounts payable within one year | 42/48 | €598k | €852k | €902k | €256k |
| Trade debts payable within one year | 44 | €2k | €0 | €11k | €714 |
| Income statement | |||||
| Gross operating margin | 9900 | €900k | €941k | €824k | €429k |
| Operating result | 9901 | €826k | €858k | €773k | €417k |
| Financial income | 75 | €31k | €10k | €929 | €3 |
| Financial charges | 65 | €50k | €217 | €14k | €175 |
| Result before taxes | 9903 | €807k | €867k | €760k | €417k |
| Income taxes | 67/77 | €198k | €216k | €238k | €101k |
| Net result for the period | 9904 | €610k | €651k | €522k | €315k |
| Result to be appropriated | 9905 | €610k | €651k | €522k | €315k |
Legal Structure
| NACE primary | Specialist medical practice(86220) |
| Legal form | Private limited company(610) |
| Incorporation | 23-01-2019 |
| Status | Active |
| Postal code | 8500 |
Establishment units
Vert
since 20192.284.607.544
Real-estate footprint
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 34354C0738/00T003 | Flanders | 1,150 m² | 1 · 233 m² | 9.1 m · 1 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
Next filing, fiscal year 2026, expected by
2026
16-07
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
07-07
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Highest result since 2022net €651k ▲24.6%
Operating result €858k, net result €651k, both a record.
31-12
Financial
Equity above €1MEq €1.17M ▲125%
3 profitable years in a row build equity to €1.17M.
23-07
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
26-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
05-07
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
28-07
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
24-07
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 3 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
Specialist medical practice86220
Names & trade names
| Legal nameNL | Vert |
Similar companies
DE VARÉ - TREMMERY
BE 0882.549.253 · Gent
DOKTER REINOUD CARTUYVELS
BE 0473.303.580 · Heusden-Zolder
DR. PHILIPPE LAMORAL
BE 0880.315.580 · Brugge
DOKTER SYLVIE VANDELANOTTE
BE 0894.556.467 · Brugge
PATCHACAP
BE 0797.163.420 · Sint-Agatha-Berchem